Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11592794 | 1.00 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL946410 | 1.00 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1434303 | 1.00 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL917170 | 1.00 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL16445915 | 1.00 | HSD17B10 (0.58) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Ammonia Solution, Strong SCHEMBL2961801 | 0.98 | HSD17B10 (0.56) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Ammonia Solution, Strong SCHEMBL2955800 | 0.98 | HSD17B10 (0.56) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL5860540 | 0.98 | HSD17B10 (0.56) | HSD17B10MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL22497668 | 0.95 | — | — | |
| SCHEMBL1071881 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801686-B | Insulin-oligomer conjugates, formulations and uses thereof | 比奥孔有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-105637075-B | Novel functional fluid compositions | 巴斯夫欧洲公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-104302747-B | Novel low viscosity functional fluid compositions | 巴斯夫欧洲公司 | 2016-12-28 | — | — | CN | disclosed |
| EP-2626368-B1 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LTD (IN) | 2016-12-21 | — | — | EP | disclosed |
| CN-105637075-A | Novel functional fluid compositions | BASF SE | 2016-06-01 | — | — | CN | disclosed |
| US-9101596-B2 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-9102758-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| EP-1773878-B1 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| CN-104302747-A | Novel low viscosity functional fluid compositions | BASF SE | 2015-01-21 | — | — | CN | disclosed |
| US-8563685-B2 | Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20110118179-A1 | CATION COMPLEXES OF INSULIN COMPOUND CONJUGATES, FORMULATIONS AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2011-05-19 | — | — | US | disclosed |
| US-7875700-B2 | polyoxyethylene glycol moieties; crystalline solid or a rod shaped crystal; proinsulin; pharmacokinetics; treating diabetes | BIOCON LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| US-7872095-B2 | Insulin-oligomer conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | RADHAKRISHNAN BALASINGAM | 2010-04-29 | — | — | US | disclosed |
| US-7605123-B2 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LTD. (IN) | 2009-10-20 | — | — | US | disclosed |
| EP-1773878-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | Nobex Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014673-A2 | INSULIN-OLIGOMER CONJUGATES, FORMULATIONS AND USES THEREOF | NOBEX CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | BIOCON LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | NOBEX CORPORATION | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019873-A1 | Cation complexes of insulin compound conjugates, formulations and uses thereof | GPR119, INSR, IAPP | HSD17B10 1399/4885MEN1 524/4885KMT2A 3285/4885 |
| US-20100105605-A1 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF | FABP2, SLC27A1, SLC27A2 | HSD17B10 1585/4885MEN1 1673/4885KMT2A 4516/4885 |
| US-20060018874-A1 | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof | FABP2, SLC27A1, SLC27A2 | HSD17B10 1557/4885MEN1 1710/4885KMT2A 4506/4885 |
| US-20110118179-A1 | CATION COMPLEXES OF INSULIN COMPOUND CONJUGATES, FORMULATIONS AND USES THEREOF | GPR119, INSR, IAPP | HSD17B10 1501/4885MEN1 536/4885KMT2A 3472/4885 |
| US-20060019874-A1 | Cation complexes of insulin compund conjugates, formulation and uses thereof | INSR, GPR119, IAPP | HSD17B10 461/4885MEN1 203/4885KMT2A 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.